What is Omicia?
Fabric Genomics operates at the intersection of artificial intelligence and clinical genetics, providing a sophisticated software platform designed to interpret whole genomes, exomes, and gene panels. By delivering clinically actionable insights, the company serves a diverse ecosystem of children's hospitals, large-scale hospital systems, and commercial laboratories. Their core technology, the Fabric Enterprise Platform, facilitates the rapid generation of physician-ready reports, which is critical for applications ranging from rare disease diagnosis to hereditary risk screening and NICU testing. By automating complex genomic analysis, Fabric Genomics addresses the growing demand for scalable, high-accuracy diagnostic tools in modern healthcare settings.
How much funding has Omicia raised?
Omicia has raised a total of $29.8M across 2 funding rounds:
Series A
$6.8M
Series B
$23M
Series A (2014): $6.8M with participation from Casdin Capital, LLC, Artis Ventures, and Bay City Capital, LLC
Series B (2016): $23M led by Ping An Ventures, LDV Partners, and Artis Ventures Management Iii
Key Investors in Omicia
Ping An Ventures
A division of the Ping An Insurance Group, this firm focuses on strategic investments across the financial services, banking, and insurance sectors with a keen interest in innovative technology.
LDV Partners
A venture firm dedicated to supporting disruptive technologies and visionary founders, with a specific focus on advancements in AI and the life sciences sector.
Artis Ventures Management Iii
A venture capital fund specializing in Tech Bio and Health, prioritizing data-driven life sciences companies that leverage engineering and AI to improve human health outcomes.
What's next for Omicia?
With the capital secured through its latest financing rounds, Fabric Genomics is well-positioned to accelerate the deployment of its AI-driven interpretation engine across global clinical markets. The strategic focus is expected to shift toward expanding the platform's interoperability with existing electronic health record systems and enhancing the depth of its variant interpretation algorithms. As the adoption of genomic medicine continues to permeate standard clinical workflows, the company is likely to prioritize partnerships that broaden its reach within the pediatric and oncology sectors, further cementing its role as a foundational infrastructure provider for the next generation of molecular diagnostics.
See full Omicia company page
